Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ: ARQT )

13.92 +0.64 (+4.82%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,772,168
Open 13.59
Bid (Size) 13.96 (27)
Ask (Size) 13.98 (9)
Prev. Close 13.28
Today's Range 13.50 - 14.36
52wk Range 3.110 - 16.20
Shares Outstanding 50,241,789
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Demystifying Arcutis Biotherapeutics: Insights From 5 Analyst Reviews
Via Benzinga
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Performance

YTD
-4.40%
-4.40%
1 Month
+2.58%
+2.58%
3 Month
+48.88%
+48.88%
6 Month
+30.46%
+30.46%
1 Year
+301.15%
+301.15%

More News

Read More
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
This American Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday
Via Benzinga
Assessing Arcutis Biotherapeutics: Insights From 4 Financial Analysts
Via Benzinga
Peeling Back The Layers: Exploring Arcutis Biotherapeutics Through Analyst Insights
Via Benzinga
This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
Via Benzinga
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
CAVA Group Posts Strong Q2 Results, Joins Bilibili, Workday And Other Big Stocks Moving Higher On Friday
Via Benzinga
Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session
Via Benzinga
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.